MeSH term
Frequency | Condition_Probility | Adult | 7 | 0.0 |
Humans | 130 | 0.0 |
Male | 12 | 0.0 |
Middle Aged | 5 | 0.0 |
Cell Line | 79 | 0.0 |
HIV Protease/metabolism | 2 | 20.0 |
HIV-1/drug effects | 2 | 4.0 |
Stereoisomerism | 2 | 0.0 |
Structure-Activity Relationship | 12 | 0.0 |
Virus Replication | 18 | 2.0 |
English Abstract | 11 | 0.0 |
HIV Infections/*virology | 2 | 2.0 |
Research Support, Non-U.S. Gov't | 86 | 0.0 |
HIV-1/*drug effects | 16 | 11.0 |
Animals | 43 | 0.0 |
Spodoptera | 2 | 0.0 |
3T3 Cells | 2 | 0.0 |
Cell Division/drug effects | 5 | 0.0 |
Cell Line, Transformed | 10 | 0.0 |
Genetic Vectors | 7 | 0.0 |
Giant Cells | 2 | 3.0 |
Hamsters | 3 | 0.0 |
Mice | 16 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 29 | 0.0 |
Transduction, Genetic | 3 | 0.0 |
CD4-Positive T-Lymphocytes/virology | 4 | 5.0 |
Comparative Study | 16 | 0.0 |
Gene Therapy/*methods | 3 | 0.0 |
HIV Infections/therapy | 2 | 13.0 |
Retroviridae/*genetics | 2 | 1.0 |
Species Specificity | 3 | 0.0 |
Cattle | 5 | 0.0 |
Chimeric Proteins/*genetics/metabolism | 2 | 33.0 |
HIV-1/*genetics/metabolism/physiology | 2 | 66.0 |
Transfection | 8 | 0.0 |
HIV Infections/drug therapy | 2 | 4.0 |
Anti-HIV Agents/*pharmacology | 2 | 1.0 |
Cells, Cultured | 20 | 0.0 |
Virus Replication/drug effects | 13 | 5.0 |
COS Cells | 2 | 0.0 |
Cercopithecus aethiops | 5 | 0.0 |
*Genes, Viral | 2 | 1.0 |
Leukocytes, Mononuclear/virology | 3 | 2.0 |
Mutagenesis | 2 | 0.0 |
RNA, Viral | 2 | 4.0 |
Protein Binding | 3 | 0.0 |
Rats | 8 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
Drug Resistance, Microbial/genetics | 3 | 3.0 |
Kinetics | 10 | 0.0 |
Models, Molecular | 2 | 0.0 |
Mutation | 4 | 0.0 |
Protein Conformation | 2 | 0.0 |
Anti-HIV Agents/*chemical synthesis/chemistry/*pharmacology | 2 | 50.0 |
HIV-1/drug effects/physiology | 3 | 18.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Microbial Sensitivity Tests | 3 | 1.0 |
Molecular Structure | 5 | 0.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Antiviral Agents/*pharmacology | 18 | 11.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
In Vitro | 3 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Female | 10 | 0.0 |
Pregnancy | 3 | 0.0 |
Anti-HIV Agents/chemistry/*pharmacology | 2 | 10.0 |
Anticoagulants/chemistry/*pharmacology | 2 | 33.0 |
Antiviral Agents/chemistry/*pharmacology | 2 | 20.0 |
Carbohydrates/chemistry/*pharmacology | 2 | 100.0 |
Diatoms/*chemistry | 2 | 100.0 |
Herpesvirus 1, Human/*drug effects | 2 | 66.0 |
Plant Extracts/chemistry/pharmacology | 2 | 20.0 |
Vero Cells | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
HIV-1/*genetics | 5 | 1.0 |
RNA, Viral/*genetics | 5 | 11.0 |
Cytopathogenic Effect, Viral | 7 | 4.0 |
Disease Progression | 2 | 0.0 |
Time Factors | 7 | 0.0 |
Virus Cultivation/methods | 2 | 33.0 |
Flow Cytometry | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
Antigens, CD4/metabolism | 3 | 0.0 |
Apoptosis/*physiology | 2 | 0.0 |
Cell Division | 2 | 0.0 |
*HIV-1 | 2 | 0.0 |
Drug Design | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Antigens, CD4/*immunology | 2 | 0.0 |
HIV Infections/*immunology | 2 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
HIV-1/*drug effects/physiology | 7 | 8.0 |
Gene Expression Regulation | 2 | 0.0 |
*Genetic Vectors | 3 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Base Sequence | 25 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
DNA Primers | 4 | 0.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Anti-HIV Agents/*chemistry/*pharmacology | 2 | 25.0 |
HIV Antibodies/*biosynthesis | 2 | 15.0 |
HIV-1/*immunology | 3 | 0.0 |
HIV-1/*physiology | 3 | 0.0 |
Lymphocytes/virology | 2 | 10.0 |
RNA, Viral/*metabolism | 2 | 4.0 |
Virus Replication/*drug effects | 11 | 7.0 |
Amino Acid Sequence | 18 | 0.0 |
Binding Sites | 4 | 0.0 |
Biological Transport | 3 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Hela Cells | 9 | 0.0 |
Molecular Sequence Data | 35 | 0.0 |
Phenotype | 4 | 0.0 |
Proviruses/genetics | 6 | 9.0 |
HIV-1/drug effects/*enzymology | 2 | 66.0 |
Microbial Sensitivity Tests/*methods | 2 | 22.0 |
Membrane Fusion | 2 | 1.0 |
T-Lymphocytes/virology | 3 | 4.0 |
HIV-1/*pathogenicity/physiology | 2 | 6.0 |
Polymerase Chain Reaction | 11 | 0.0 |
DNA Replication/drug effects | 2 | 1.0 |
HIV-1/physiology | 2 | 2.0 |
Interferon-alpha/*pharmacology | 2 | 1.0 |
Interferon-beta/*pharmacology | 2 | 3.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Virus Integration | 2 | 3.0 |
HIV-1 Reverse Transcriptase/genetics | 2 | 5.0 |
DNA, Viral/analysis | 3 | 0.0 |
HIV-1/genetics/*physiology | 5 | 4.0 |
RNA, Viral/analysis | 3 | 1.0 |
*Virus Replication | 6 | 2.0 |
*HIV Long Terminal Repeat | 3 | 3.0 |
Macaca mulatta | 2 | 0.0 |
Neutralization Tests | 5 | 1.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
AIDS Vaccines | 2 | 16.0 |
B-Lymphocytes/*immunology | 3 | 0.0 |
HIV-1/*immunology/physiology | 2 | 5.0 |
Rabbits | 2 | 0.0 |
Cell Transformation, Viral | 4 | 1.0 |
Human T-lymphotropic virus 1/*genetics | 3 | 5.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
HIV Envelope Protein gp120/*immunology | 2 | 1.0 |
Blotting, Southern | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Adenosine Deaminase/metabolism | 2 | 10.0 |
Drug Resistance, Microbial | 2 | 1.0 |
Half-Life | 3 | 0.0 |
Macaca fascicularis | 3 | 1.0 |
Aged | 2 | 0.0 |
Biopsy | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Cell Death | 2 | 0.0 |
Drug Synergism | 7 | 0.0 |
Nucleic Acid Conformation | 3 | 0.0 |
RNA, Catalytic/*metabolism | 2 | 13.0 |
Recombination, Genetic | 2 | 0.0 |
Genes, Viral | 2 | 0.0 |
Gene Expression/drug effects | 2 | 0.0 |
Genes, pol/genetics | 2 | 40.0 |
Lamivudine | 2 | 16.0 |
T-Lymphocytes | 4 | 1.0 |
Zalcitabine/*analogs & derivatives/pharmacology | 2 | 66.0 |
Zidovudine/*pharmacology | 6 | 23.0 |
HIV-1 Reverse Transcriptase | 7 | 11.0 |
*Virus Integration | 2 | 2.0 |
Cytopathogenic Effect, Viral/drug effects | 9 | 39.0 |
HIV Core Protein p24/biosynthesis | 2 | 4.0 |
RNA, Viral/biosynthesis | 2 | 4.0 |
RNA/analysis | 2 | 0.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Biological Availability | 2 | 0.0 |
Dogs | 2 | 0.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
*Mutation | 4 | 0.0 |
RNA-Directed DNA Polymerase/*genetics | 2 | 25.0 |
Reverse Transcriptase Inhibitors | 3 | 15.0 |
Zidovudine/pharmacology | 6 | 10.0 |
Plasmids | 4 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
RNA, Antisense/*genetics | 2 | 6.0 |
Chromosome Mapping | 2 | 0.0 |
T-Lymphocytes/microbiology | 2 | 8.0 |
RNA-Directed DNA Polymerase/analysis | 3 | 11.0 |
Thionucleosides/*pharmacology | 2 | 100.0 |
Microscopy, Electron | 3 | 0.0 |
RNA-Directed DNA Polymerase/metabolism | 4 | 5.0 |
Down-Regulation | 2 | 0.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
DNA, Viral/genetics | 2 | 1.0 |
Dideoxynucleosides/*pharmacology | 3 | 37.0 |
HIV Antigens/analysis | 2 | 5.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Blotting, Northern | 2 | 0.0 |
Oligonucleotide Probes | 3 | 0.0 |
Restriction Mapping | 5 | 0.0 |
Chemotaxis, Leukocyte | 2 | 1.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Chromosome Deletion | 2 | 0.0 |
Cytochrome c Group/genetics | 2 | 33.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
HIV/*drug effects | 3 | 12.0 |
Giant Cells/immunology | 2 | 16.0 |
Plaque Assay | 2 | 2.0 |
HIV/*drug effects/physiology | 2 | 20.0 |
Phosphorylation | 2 | 0.0 |
Deoxyadenosines/*analogs & derivatives/pharmacology | 2 | 66.0 |
*Dideoxyadenosine/*analogs & derivatives | 2 | 66.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
HLA-DR Antigens | 3 | 0.0 |
HLA-DR4 Antigen | 2 | 3.0 |
Genes, MHC Class II | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |